RxDoctor Payments Data

Edgar Rodriguez Gonzalez, MD

Pulmonary Disease · San Juan, PRNPI 1639274814

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by GSK at 31.8% of the total.

$5,248in general payments, 2019–2025

Across 213 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Biocryst US Sales Co., LLC$469
  • Mylan Specialty L.p.$457
  • Teva Pharmaceuticals USA, Inc.$252
  • Mylan LLC$229
  • plus $653 from 7 others

What the payments were for

  • Food & beverage$5,14898%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,248 in reported general payments places this provider in the 75th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$23,301
Medicare patients
105
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EsbrietPirfenidone11$115,174
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$84,529
Breo ElliptaFluticasone/Vilanterol164$67,983
Wixela InhubFluticasone Propion/Salmeterol364$49,687
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$19,325
SymbicortBudesonide/Formoterol Fumarate53$13,365
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$11,300
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate36$10,320
Spiriva RespimatTiotropium Bromide15$8,096
Azelastine Hcl266$7,008
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,731
Albuterol Sulfate HfaAlbuterol Sulfate122$4,527
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,828
SynthroidLevothyroxine Sodium29$1,961
Methylprednisolone131$1,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,671$158,244304 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,518$32,68979 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$20$19,39638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →